跳至主要内容
临床试验/NCT03341832
NCT03341832已完成2 期

A Randomized, Double-blind, Active- and Placebo-controlled, Parallel, Multicenter, Phase II an Exploratory Clinical Trial to Evaluate the Efficacy and Safety NVP-1203 in Patients With Acute Low Back Pain

NVP Healthcare1 个研究点 分布在 1 个国家目标入组 91 人开始时间: 2018年1月31日最近更新:
适应症
干预措施
相关药物

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
91
试验地点
1
主要终点
VAS Pain Intensity

研究概览

简要总结

The purpose of this study is to evaluate the efficacy and safety NVP-1203 in patients with Acute low back pain

详细描述

This study is a randomized, double-blind, active- and placebo-controlled, parallel, phase II study to evaluate efficacy and safety of NVP-1203 in patients with Acute low back pain

研究设计

研究类型
Interventional
分配方式
Randomized
干预模型
Parallel
主要目的
Treatment
盲法
Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

入排标准

年龄范围
19 Years 至 —(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • Subjects who have ability to comprehend the contents of study and before participating in trial and have willingness to sign of informed consent in writing
  • 19 Years and older
  • A patient has symptom of acute low back pain

排除标准

  • Subjects who cannot prohibit anti-inflammatory drug or muscle relaxants during clinical trial
  • Inadequate subject for the clinical trial by the investigator's decision

研究组 & 干预措施

NVP-1203

Experimental

NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose

干预措施: NVP-1203 (Drug)

NVP-1203

Experimental

NVP-1203 plus NVP-1203-R placebo for up to 7 days, oral dose

干预措施: NVP-1203-R placebo (Drug)

NVP-1203-R

Active Comparator

NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose

干预措施: NVP-1203-R (Drug)

NVP-1203-R

Active Comparator

NVP-1203-R plus NVP-1203 placebo for up to 7 days, oral dose

干预措施: NVP-1203 placebo (Drug)

Placebo

Placebo Comparator

NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose

干预措施: NVP-1203 placebo (Drug)

Placebo

Placebo Comparator

NVP-1203 placebo plus NVP-1203-R placebo for up to 7 days, oral dose

干预措施: NVP-1203-R placebo (Drug)

结局指标

主要结局

VAS Pain Intensity

时间窗: 3, 7 days

Improvement in VAS compared to baseline

次要结局

  • Finger to Floor Distance (FFD)(3, 7 days)
  • Oswestry Disability Index(ODI)(3, 7 days)
  • Investigator Global Assessment of Response to Therapy(IGART)(7 days)

研究者

发起方
NVP Healthcare
申办方类型
Industry
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验